الإحصائيات الأساسية
| LEI | 52990076U5YRLVGDJE40 |
| CIK | 764195 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to VBI Vaccines Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| January 3, 2025 |
VBI Vaccines Announces Completion of Sales Process to K2 Exhibit 99.1 VBI Vaccines Announces Completion of Sales Process to K2 CAMBRIDGE, Mass. – January 3, 2025 – VBI Vaccines Inc. (“VBI” or the “Company”) today announced, that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) and its previously announced sale and investment solicitation process, the Company completed the transa |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| January 3, 2025 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company VBI Vaccines Inc. (the “Company”) 160 Second Street, 3rd Floor Cambridge, Massachusetts, United States 02142 2. Dates of Material Change January 3, 2025. 3. News Releases A press release was disseminated on January 3, 2025, through newswire and the Company’s website. 4 Summary of Material Changes On January 3, 2025, t |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2025 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| December 10, 2024 |
Exhibit 99.1 VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission CAMBRIDGE, Mass. – December 10, 2024 – VBI Vaccines Inc. (“VBI” or the “Company”) today provided an update on the restructuring proceedings announced on July 30, 2024. Restructuring Transaction Following the conclusion of the sale and |
|
| December 10, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| August 2, 2024 |
VBI Vaccines Provides an Update on its Restructuring Proceedings Exhibit 99.1 VBI Vaccines Provides an Update on its Restructuring Proceedings CAMBRIDGE, Mass. (August 2, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the U |
|
| July 30, 2024 |
Exhibit 99.1 VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives CAMBRIDGE, Mass. (July 30, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) (“Court”) |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 25, 2024 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 25, 2024 |
VBI Vaccines Announces Results of Annual General Meeting Exhibit 99.1 VBI Vaccines Announces Results of Annual General Meeting CAMBRIDGE, Mass. (June 25, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the “Meeting”). T |
|
| May 29, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 29, 2024 |
Exhibit 99.1 VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients ● Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 ● The partial response, which demon |
|
| May 24, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
Exhibit 10.7 CONFIDENTIAL Execution Version [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT by and among Purchaser, Seller, VBI Vaccines Inc. (as Guarantor) and Brii Biosciences, Inc. (as Purchaser Guarantor) D |
|
| May 15, 2024 |
Exhibit 10.9 SIF Project No. 812-815774 STRATEGIC INNOVATION FUND AMENDMENT AGREEMENT NO. 2 This Amendment Agreement made Between: HIS MAJESTY THE KING IN RIGHT OF CANADA (“His Majesty”), as represented by the Minister of Industry (the “Minister”) And: Variation Biotechnologies Inc., a corporation duly incorporated under the laws of Canada, having its head office located at 310 Hunt Club Road Suit |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
Exhibit 10.6 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. PURCHASE AGREEMENT This PURCHASE AGREEMENT (“Purchase Agreement”) is entered into as of 13 February, 2024 (the “Effective Date”) between, VBI VACCINES, INC. a company organiz |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI VACCI |
|
| May 15, 2024 |
VBI Vaccines Reports First Quarter 2024 Financial Results Exhibit 99.1 VBI Vaccines Reports First Quarter 2024 Financial Results ● PreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 ● Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) announced in April – additional data expected |
|
| May 15, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT May 15, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follo |
|
| May 15, 2024 |
Exhibit 10.5 FOURTH AMENDMENT TO LOAN AND GUARANTY AGREEMENT, WAIVER AND FORBEARANCE AGREEMENT This FOURTH AMENDMENT TO LOAN AND GUARANTY AGREEMENT, WAIVER AND FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of February 13, 2024 (the “Fourth Amendment Effective Date”), by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“VBI Cda”, and in its capacity as borrowe |
|
| May 15, 2024 |
Up to $8,468,289 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-267109 PROSPECTUS SUPPLEMENT (To the Prospectus Dated September 6, 2022) Up to $8,468,289 Common Shares We have entered into an At The Market Offering Agreement (the “Sales Agreement”), dated May 15, 2024, with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright” or the “sales agent”), relating to our common shares, no par value per share ( |
|
| May 15, 2024 |
Side Letter, dated February 13, 2024, among VBI Vaccines Inc, and Brii Biosciences Limited. Exhibit 10.8 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. LETTER AGREEMENT This LETTER AGREEMENT (the “Agreement”) is entered into as of February 13, 2024 (the “Effective Date”) between VBI VACCINES INC., a British Columbia corporat |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 17, 2024 |
VBIV / VBI Vaccines Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d816314dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9)* VBI Vaccines Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 91822J 202 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (N |
|
| April 16, 2024 |
Exhibit 10.65 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 16, 2024 |
Exhibit 10.66 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 16, 2024 |
Exhibit 10.68 AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the “Amendment”), effective as of January 1st, 2024 (the “Effective Date”), is by and between Variation Biotechnologies Inc., a corporation incorporated pursuant to the laws of Canada (the “Company”) having an address of 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1 and F. Diaz-Mitoma Professional Corporatio |
|
| April 16, 2024 |
Exhibit 10.62 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 16, 2024 |
Exhibit 97.1 VBI Vaccines Inc. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of VBI Vaccines Inc. (the “Company”) is hereby adopted as of November 21, 2023, in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings as set for in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Section 4 of this Pol |
|
| April 16, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 16, 2024 |
VBI Vaccines Reports Full Year 2023 Financial Results Exhibit 99.1 VBI Vaccines Reports Full Year 2023 Financial Results ● PreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 ● Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone ● Early data from randomized Phase 2b study of VBI-1901 in recurrent gliobl |
|
| April 16, 2024 |
Exhibit 10.64 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37769 VBI VACCINES INC. (Exact na |
|
| April 16, 2024 |
Exhibit 10.63 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 16, 2024 |
Exhibit 10.67 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| April 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-267109 PROSPECTUS SUPPLEMENT (To the Prospectus Dated September 6, 2022) 2,272,728 Common Shares Warrants to Purchase up to 2,272,728 Common Shares Placement Agent Warrants to Purchase up to 136,364 Common Shares 2,409,092 Common Shares Underlying the Warrants and the Placement Agent Warrants We are offering (i) 2,272,728 common shares, no par |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| April 11, 2024 |
Exhibit 4.2 PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT VBI VACCINES INC. Warrant Shares: Issue Date: April 11, 2024 Initial Exercise Date: April 11, 2024 THIS PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| April 11, 2024 |
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CAMBRIDGE, Mass. (April 9, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for the sale and issuance of 2,272, |
|
| April 11, 2024 |
Exhibit 99.2 VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CAMBRIDGE, Mass. (April 11, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering pri |
|
| April 11, 2024 |
Exhibit 4.1 COMMON SHARE PURCHASE WARRANT VBI VACCINES INC. Warrant Shares: Issue Date: April 11, 2024 Initial Exercise Date: April 11, 2024 THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| April 11, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 9, 2024, between VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers |
|
| April 3, 2024 |
Exhibit 99.1 VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma ● Data highlighted in oral presentation at World Vaccine Congress 2024 on April 3, 2024 ● Early data from patients eligible for evaluation at week 12 show two observations of stable disease, indicating no tumor progression, in VBI-1901 treatment a |
|
| April 3, 2024 |
Slide Presentation, dated April 3, 2024 (furnished pursuant to Item 7.01) Exhibit 99.2 |
|
| April 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2024 |
Exhibit 99.1 VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform ● VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform ● The partnership will direct CAD$28 million o |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| February 14, 2024 |
Exhibit 99.1 VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences ● VBI to receive up to $33 million in consideration, subject to achievement of certain activities, for: ◌ VBI’s manufacturing capabilities and certain related assets at Rehovot manufacturing facility ◌ Intellectual property for VBI-2601, VBI’s |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| February 6, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2024 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 26, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| December 12, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 29, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 28, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 20, 2023 |
CA91822J2020 / VBI Vaccines Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 20, 2023 |
Exhibit 99.1 VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting CAMBRIDGE, Mass. (November 20, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biom |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
Exhibit 10.9 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this “Forbearance Agreement”) is entered into as of November 13, 2023 (“Effective Date”) by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), VBI VACCINES INC., a British Columbia corporation (“Parent”, and together with Borrower Representative, and any other Person from time to time |
|
| November 14, 2023 |
VBI Vaccines Reports Third Quarter 2023 Financial Results Exhibit 99.1 VBI Vaccines Reports Third Quarter 2023 Financial Results ● PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 ● Continued execution across earlier-stage pipeline, including: ○ Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients ○ Interim Phase 1 data announced for pan-coronavirus candid |
|
| November 14, 2023 |
Exhibit 10.7 855 Boylston Street, 10th Floor Boston, MA 02116 October 27, 2023 Variation Biotechnologies Inc. 310 Hunt Club Road East, Suite 201 Ottawa Ontario Canada K1V 1C1 Attention: Nell H. Beattie Re: Extension of Delivery Due Date for Compliance Certificate for period ended 9/30/23 Ladies and Gentlemen: Reference is made to the Loan and Guaranty Agreement dated as of the date hereof (includi |
|
| November 14, 2023 |
Exhibit 10.4 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. AMENDED & RESTATED COLLABORATION AND LICENSE AGREEMENT This AMENDED & RESTATED COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of July 5, 2023 (the “Effe |
|
| November 14, 2023 |
Exhibit 10.3 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of July 5, 2023 (the “Effective Date”) between VBI VACCINES INC. |
|
| November 14, 2023 |
Letter Agreement, dated July 5, 2023, by and between VBI Vaccines Inc. and Brii Biosciences. Exhibit 10.6 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. LETTER AGREEMENT This LETTER AGREEMENT (the “Agreement”) is entered into as of July 5, 2023 (the “Effective Date”) between VBI VACCINES INC., a company organized under the la |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
Supply Agreement, dated July 5, 2023, by and between VBI Vaccines Inc. and Brii Biosciences. Exhibit 10.5 [**] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this document because it is both not material and is the type that the registrant treats as private or confidential. SUPPLY AGREEMENT This SUPPLY AGREEMENT (the “Agreement”) is entered into as of July 5, 2023 (the “Effective Date”) by and between BRII BIOSCIENCES LIMITED, an exempted compan |
|
| November 14, 2023 |
Exhibit 10.8 855 Boylston Street, 10th Floor Boston, MA 02116 November 3, 2023 Variation Biotechnologies Inc. 310 Hunt Club Road East, Suite 201 Ottawa Ontario Canada K1V 1C1 Attention: Nell H. Beattie Re: Extension No. 2 of Delivery Due Date for Compliance Certificate for period ended 9/30/23 Ladies and Gentlemen: Reference is made to the Loan and Guaranty Agreement dated as of the date hereof (i |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI V |
|
| November 3, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| October 26, 2023 |
Exhibit 99.1 VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program ● Preclinical data suggests novel mRNA-launched eVLPs (“MLE”) generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone ● In addition to immunologic benefits, new MLE technology enables manufacturing of particulate vaccine |
|
| September 27, 2023 |
Exhibit 99.1 VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern ● First clinical data from a pan-coronavirus vaccine candidate ● Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple animal coronaviruses including bat and |
|
| September 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Comm |
|
| September 7, 2023 |
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM Exhibit 99.1 VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM ● Multi-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM ● FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent setting, following encouraging Phase 1/2a study results ● Interim data analysis |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| September 6, 2023 |
Exhibit 99.1 VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B ● BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up ● Significantly increased seroconversion rate is str |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| August 14, 2023 |
Exhibit 10.4 THIRD AMENDMENT TO LOAN AND GUARANTY AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT This THIRD AMENDMENT TO LOAN AND GUARANTY AGREEMENT AND AMENDMENT TO PLEDGE AND SECURITY AGREEMENT “Amendment”) is entered into as of July 5, 2023 (the “Third Amendment Effective Date”), by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (“Borrower Representative”), V |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI VACCIN |
|
| August 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2023 |
VBI Vaccines Reports Second Quarter 2023 Financial Results Exhibit 99.1 VBI Vaccines Reports Second Quarter 2023 Financial Results ● PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 48% quarter-over-quarter from Q1 to Q2 2023 - redefined, highly targeted commercial field team deployed at the end of Q2 ● Expanded hepatitis B collaboration with Brii Biosciences announced in July for $15 million upfront, including a $3 million equi |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incor |
|
| July 24, 2023 |
Exhibit 99.1 VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares CAMBRIDGE, Mass. (July 24, 2023) – VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| July 20, 2023 |
CA91822J2020 / VBI Vaccines Inc / Brii Biosciences Ltd - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VBI VACCINES INC. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 91822J202 (CUSIP Number) July 10, 2023 (Date of Event Which Required Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| July 19, 2023 |
Exhibit 99.1 VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults ● PreHevbri® is the only approved 3-antigen hepatitis B vaccine for adults in the Netherlands and Belgium ● Product to be launched via marketing and distribution partner, Valneva CAMBRIDGE, Mass. (July 19, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a bioph |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| July 11, 2023 |
Consent of Haynes and Boone, LLP (included in Exhibit 5.3) Exhibit 5.3 July 10, 2023 VBI Vaccines Inc. 160 Second Street, Floor 3 Cambridge, MA 02142 Ladies and Gentlemen: We have acted as counsel to VBI Vaccines Inc. (the “Company”), a corporation incorporated under the Business Corporations Act (British Columbia), in connection with the filing with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act |
|
| July 11, 2023 |
Consent of Haynes and Boone, LLP (included in Exhibit 5.4) Exhibit 5.4 July 10, 2023 VBI Vaccines Inc. 160 Second Street, Floor 3 Cambridge, MA 02142 Ladies and Gentlemen: We have acted as counsel to VBI Vaccines Inc. (the “Company”), a corporation incorporated under the Business Corporations Act (British Columbia), in connection with the filing with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| July 7, 2023 |
Exhibit 4.1 VBI VACCINES INC. Warrant To Purchase Common Shares Warrant No.: Number of Common Shares: Date of Issuance: [], 2023 (“Issuance Date”) VBI Vaccines Inc., a company organized under the laws of British Columbia (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof o |
|
| July 7, 2023 |
Exhibit 99.1 VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants CAMBRIDGE, Mass. (July 5, 2023) – VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public |
|
| July 7, 2023 |
10,909,091 Common Shares Warrants to Purchase up to 10,909,091 Common Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-267109 PROSPECTUS SUPPLEMENT (To Prospectus dated September 6, 2022) 10,909,091 Common Shares and Warrants to Purchase up to 10,909,091 Common Shares We are offering 10,909,091 common shares and accompanying common warrants to purchase up to 10,909,091 common shares in this offering. The combined public offering price for each common share and |
|
| July 7, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-267109 PROSPECTUS SUPPLEMENT (To Prospectus dated September 6, 2022) 1,818,182 Common Shares Warrants to Purchase 1,818,182 Common Shares and Up to 1,818,182 Common Shares Underlying the Warrants We are offering 1,818,182 common shares and accompanying common warrants to purchase 1,818,182 common shares in this offering. The combined offering p |
|
| July 7, 2023 |
Exhibit 99.2 VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering Approximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be received by VBI CAMBRIDGE, Mass. (July 6, 2023) – VBI Vaccines Inc. (NASDA |
|
| July 7, 2023 |
Exhibit 1.1 VBI Vaccines Inc. 10,909,091 Common Shares 10,909,091 Common Warrants to Purchase 10,909,091 Common Shares Underwriting Agreement July 6, 2023 RAYMOND JAMES & ASSOCIATES, INC. As Representative of the Several Underwriters named in Schedule A c/o Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, Florida 33716 Ladies and Gentlemen: 1. VBI Vaccines Inc., a company inco |
|
| July 5, 2023 |
Exhibit 99.1 VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties ● Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region ● VBI will receive gross proceeds of $15 million in upfront paym |
|
| July 5, 2023 |
Subject to Completion, dated July 5, 2023 Filed pursuant to Rule 424(b)(5) Registration No. 333-267109 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| July 5, 2023 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of July 5, 2023, by and between VBI Vaccines Inc., a British Columbia corporation (the “Company”), and Brii Biosciences Limited, an exempted company organized under the laws of the Cayman Islands (“Investor”). PREAMBLE WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Co |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 5, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| June 23, 2023 |
VBI Vaccines Announces Results of Annual General Meeting Exhibit 99.1 VBI Vaccines Announces Results of Annual General Meeting CAMBRIDGE, Mass. (June 23, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 23, 2023 (the “Meeting”). T |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 15, 2023 |
Exhibit 99.1 VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults ● PreHevbri® is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. ● Product to be launched via marketing and distribution partner, Valneva CAMBRIDGE, Mass. (June 15, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 7, 2023 |
VBI Vaccines Announces Poster Presentation at EASL 2023 Exhibit 99.1 VBI Vaccines Announces Poster Presentation at EASL 2023 CAMBRIDGE, Mass. (June 7, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hep |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
VBI Vaccines Reports First Quarter 2023 Financial Results Exhibit 99.1 VBI Vaccines Reports First Quarter 2023 Financial Results ● PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy chains including Costco, RiteAid, and Walmart ● Therapeutic Hepatitis B: Initial Phase 2 study data announced |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI VACCI |
|
| May 15, 2023 |
Exhibit 10.4 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Business Confidential – Protected B THIS IS AN AMENDING AGREEMENT BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corporation of the Government of Canada whose h |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2023 |
Submission Proof - Z:\2023 OPERATIONS\2023 EDGAR\04 April\VBI Vaccines Inc\04-21-2023\Form DEF 14A\Draft\Production\VBI Vaccines Inc 04-21-2023 Form DEF 14A. |
|
| May 1, 2023 |
Submission Proof - Z:\2023 OPERATIONS\2023 EDGAR\04 April\VBI Vaccines Inc\04-21-2023\Form DEF 14A\Draft\Production\VBI Vaccines Inc 04-21-2023 Form DEF 14A. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2023 |
VBI Vaccines Appoints Vaughn Himes to Board of Directors Exhibit 99.1 VBI Vaccines Appoints Vaughn Himes to Board of Directors CAMBRIDGE, Mass. (April 25, 2023) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors. Dr. Himes has a 30+ |
|
| April 7, 2023 |
VBIV / VBI Vaccines Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 4, 2023 |
Exhibit 10.1 April 3, 2023 Nell Beattie 37 Shipway Place, Unit 37 Charlestown, MA 02129 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of April 3, 2023 by and between Nell Beattie, on the one hand (the “Executive”), and VBI Vaccines (Delaware) Inc., a Delaware corporation (the “Company”), on the other hand. WHEREAS, the Executive has been an Executive and an Officer of |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 4, 2023 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split ● VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 ● Cost-saving measures expected to reduce quarterly o |
|
| March 13, 2023 |
EX-10.49 5 ex10-49.htm Exhibit 10.49 AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the “Amendment”), effective as of January 1st, 2023 (the “Effective Date”), is by and between Variation Biotechnologies Inc., a corporation incorporated pursuant to the laws of Canada (the “Company”) having an address of 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1 and F. Diaz-Mitoma |
|
| March 13, 2023 |
Exhibit 10.51 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Business Confidential – Protected B THIS IS AN AMENDING AGREEMENT BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corporation of the Government of Canada whose |
|
| March 13, 2023 |
Exhibit 10.48 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Amendment Agreement # 1 (CEPI Identification #: [●]) Agreement Summary COUNTERPARTY INFORMATION Name: Variation Biotechnologies Inc. (“Awardee “) Mailing Address: 160 Secon |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37769 VBI VACCINES INC. (Exact na |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 13, 2023 |
EX-10.50 6 ex10-50.htm Exhibit 10.50 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT This License Agreement (the “Agreement”) is made as of September 1, 2021 (the “Effective Date”), by and among Ferring International |
|
| March 13, 2023 |
VBI Vaccines Reports Full Year 2022 Financial Results Exhibit 99.1 VBI Vaccines Reports Full Year 2022 Financial Results ● Access to PreHevbrio [Hepatitis B Vaccine (Recombinant)] continues to broaden in the U.S. and beyond, with additional approvals received in 2022 in Europe and Canada ● Clinical data expected throughout 2023 from: (i) VBI-2601: two ongoing Phase II studies in chronically infected hepatitis B (HBV) patients, and (ii) VBI-2901: firs |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| February 28, 2023 |
Slide Presentation of VBI Vaccines Inc. dated February 2023 (furnished pursuant to Item 7.01) Exhibit 99.2 |
|
| February 28, 2023 |
Slide Presentation of VBI Vaccines Inc. dated February 2023 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| February 15, 2023 |
Exhibit 99.1 VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B ● VBI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed ● Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination induced meaningfully stronger anti-hepatitis B |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction (Commission (IRS Employe |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| December 27, 2022 |
Slide Presentation of VBI Vaccines Inc. dated December 2022 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| December 8, 2022 |
Exhibit 99.1 VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults OTTAWA, ON and CAMBRIDGE, MA. (December 8, 2022) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™ [3-antigen Hepati |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| December 6, 2022 |
CEPI boosts ‘Coronavirus X’ vaccine search with expanded VBI Vaccines deal Exhibit 99.1 CEPI boosts ‘Coronavirus X’ vaccine search with expanded VBI Vaccines deal ● CEPI and VBI expand scope of partnership to target multiple coronavirus threats ● Vaccine platform presents multiple antigens, mimicking natural form of the virus December 6, 2022; OSLO, Norway and CAMBRIDGE, MA: The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfol |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 22, 2022 |
Exhibit 99.1 VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting CAMBRIDGE, Mass. (November 22, 2022) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI V |
|
| November 10, 2022 |
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update ● Q3 marked a meaningful quarter for partnerships with a recently announced prophylactic hepatitis B commercialization collaboration in certain European countries with Valneva, and a clinical collaboration in glioblastoma with Agenus ● PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], launched in th |
|
| November 10, 2022 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 26, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or princip |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| October 12, 2022 |
Exhibit 99.1 VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients - Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 - Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| September 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Comm |
|
| September 29, 2022 |
Exhibit 99.1 VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901 ? Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses ? Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also incl |
|
| September 21, 2022 |
Exhibit 99.1 VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting CAMBRIDGE, M.A. ? September 21, 2022 ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the phy |
|
| September 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Comm |
|
| September 15, 2022 |
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures Exhibit 99.1 VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures CAMBRIDGE, Mass. (September 15, 2022) ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, |
|
| September 15, 2022 |
Exhibit 10.1 second AMENDMENT TO LOAN AND GUARANTY AGREEMENT AND AFFIRMATION OF PLEDGE AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND GUARANTY AGREEMENT (this ?Amendment?) is entered into as of September 14, 2022 (the ?Second Amendment Effective Date?), by and among VARIATION BIOTECHNOLOGIES INC., a Canadian federal corporation (?Borrower Representative?), VBI VACCINES INC., a British Co |
|
| September 15, 2022 |
Exhibit 10.2 THIS WARRANT AND THE WARRANT SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE OR FOREIGN SECURITIES LAWS AND, EXCEPT AS SET FORTH IN Sections 6.1 and 6.2 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN A TRANSACTION |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Comm |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| September 8, 2022 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| September 8, 2022 |
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri® Exhibit 99.1 Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri? SAINT-HERBLAIN, France and CAMBRIDGE, Mass. (September 8, 2022) ? Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri? [Hepatitis B va |
|
| September 2, 2022 |
VBI Vaccines Inc. 160 Second Street, Floor 3 Cambridge, MA 02142 (617) 830-3031 VBI Vaccines Inc. 160 Second Street, Floor 3 Cambridge, MA 02142 (617) 830-3031 September 2, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Tim Buchmiller Re: VBI Vaccines Inc. Registration Statement on Form S-3, originally filed on August 26, 2022 File No. 333-267109 (the ?Registration Statement?) Ladies an |
|
| August 26, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| August 26, 2022 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 26, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or princip |
|
| August 26, 2022 |
EX-FILING FEES 4 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables FORM S-8 VBI VACCINES INC. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Equity Common Shares, no par value Rule 457(c) and Rule 457(h) 311,235 $ 0. |
|
| August 26, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) VBI VACCINES INC. |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI VACCIN |
|
| August 8, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2022 |
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? PreHevbrio? [Hepatitis B Vaccine (Recombinant)] launched in the U.S. at the end of Q1 2022 ? advancing through commercial stage gates required to enable broad access to the 3-antigen adult hepatitis B (HBV) vaccine ? FDA Orphan Drug Designation received for VBI-1901 for treatment of glioblastoma |
|
| July 12, 2022 |
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer EX-99.1 2 ex99-1.htm Exhibit 99.1 VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer CAMBRIDGE, M.A. – July 12, 2022 – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. |
|
| July 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| July 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2022 |
Exhibit-99.1 VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022 - Presentation title: ?Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine? CAMBRIDGE, M.A.? June 28, 2022 ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company |
|
| June 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 23, 2022 |
VBI Vaccines Announces Results of Annual General Meeting Exhibit 99.1 VBI Vaccines Announces Results of Annual General Meeting CAMBRIDGE, Mass. (June 22, 2022) ? VBI Vaccines Inc. (Nasdaq: VBIV) (?VBI? or the ?Company?), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 22, 2022 (the ?Meeting?). T |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 22, 2022 |
Exhibit 99.1 VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma - FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients - Next steps for development of VBI-1901 : ? Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated appro |
|
| June 22, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| June 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2022 |
Exhibit 99.1 VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting - Median overall survival and 18-month overall survival data continue to show improvements over historical controls1 - One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline - |
|
| June 1, 2022 |
Exhibit 99.1 VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri?, a 3-Antigen Adult Hepatitis B Vaccine - PreHevbri? is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom - Approval follows the European Commission?s marketing authorisation, granted in April 2022 CAMBRIDGE, Mass. (June 1, 2022) ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceut |
|
| June 1, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 19, 2022 |
Exhibit 99.1 VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio? at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 CAMBRIDGE, Mass. (May 19, 2022) ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economic |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 10.5 SIF Project No. 812-815774 Amendment No. 1 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. STRATEGIC INNOVATION FUND AMENDMENT AGREEMENT NO. 1 This Amendment Agreement made Between: HER MAJESTY THE QUEEN IN RIGHT OF CANAD |
|
| May 9, 2022 |
Exhibit 10.4 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Business Confidential ? Protected B THIS IS AN AMENDING AGREEMENT (referred to herein as ?Amendment Six?) BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corpora |
|
| May 9, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2022 |
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99-1 VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update - VBI?s 3-antigen adult HBV vaccine available in the U. |
|
| May 9, 2022 |
Exhibit 10.1 AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the ?Amendment?), effective as of December 16th, 2021 (the ?Effective Date?), is by and between Variation Biotechnologies Inc., a corporation incorporated pursuant to the laws of Canada (the ?Company?) having an address of 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1 and F. Diaz-Mitoma Professional Corporati |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37769 VBI VACCI |
|
| May 2, 2022 |
Exhibit 99.1 VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri?, a 3-Antigen Adult Hepatitis B Vaccine - PreHevbri? is the only approved 3-antigen hepatitis B vaccine for adults in the EU and EEA - Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in February 2022 - Regulatory review in the United Kingdom |
|
| May 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2022 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| April 29, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| April 18, 2022 |
PRE 14A 1 formpre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ |
|
| April 5, 2022 |
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program Exhibit 99.1 VBI Vaccines Announces New Data and Progress of VBI-2900, VBI?s eVLP Coronavirus Program - New Phase 1b clinical data of VBI-2905 (monovalent, Beta) demonstrated a well-tolerated safety profile and an encouraging ability to boost and broaden the immune response against the Beta variant - New preclinical data demonstrated VBI-2901 (trivalent, pan-coronavirus) induced antibody titers th |
|
| April 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| April 1, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 29, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 29, 2022 |
Exhibit 99.1 VBI Vaccines Announces PreHevbrio? is Now Available in the United States for the Prevention of Hepatitis B in Adults - PreHevbrio? [Hepatitis B Vaccine (Recombinant)] is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - FDA approval of PreHevbrio received in November 2021 - PreHevbrio added to ACIP list of recommended adult HBV vaccines in February 2022 - Wholes |
|
| March 15, 2022 |
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference Exhibit 99.1 VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, M.A. ? March 15, 2022 ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI?s President and CEO, will participate in an analyst-led fireside chat at the 32n |
|
| March 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 7, 2022 |
Exhibit 10.51 CONFIDENTIAL EXECUSION VERSION [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Amendment 2 to collaboration and license agreement This Amendment #2 (hereinafter ?Amendment 2?) is signed as of the signature date(s) below |
|
| March 7, 2022 |
[***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 7, 2022 |
Exhibit 10.25 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Business Confidential ? Protected B THIS IS AN AMENDING AGREEMENT BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corporation forming part of the Government of |
|
| March 7, 2022 |
Exhibit 10.26 [***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. Business Confidential ? Protected B THIS IS AN AMENDING AGREEMENT (referred to herein as ?Amendment Five?) BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corpo |
|
| March 7, 2022 |
[***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 7, 2022 |
[***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 7, 2022 |
Exhibit 10.1B+ VBI Vaccines INC. Incentive PLAN Effective May 6, 2016 As amended December 16, 2021 PART I ? GENERAL PROVISIONS 1. PREAMBLE AND DEFINITIONS 1.1 Title. The Plan described in this document shall be called the ?VBI Vaccines Inc. Incentive Plan? 1.2 Purpose of the Plan. The purposes of the Plan are: (a) to promote a further alignment of interests between officers, employees and other el |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37769 VBI VACCINES INC. (Exact na |
|
| March 7, 2022 |
Exhibit 99.1 VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022 - Prophylactic Hepatitis B (HBV): - FDA approval of PreHevbrio? [Hepatitis B Vaccine (Recombinant)] received in November 2021 - PreHevbrio added to ACIP list of recommended adult HBV vaccines in February 2022 - U.S. commercial launch of PreHevbrio expected at th |
|
| March 7, 2022 |
[***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 7, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commissio |
|
| March 7, 2022 |
[***] Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 7, 2022 |
Exhibit 10.52 AMENDMENT TO CONSULTING AGREEMENT This Amendment to Consulting Agreement (the ?Amendment?), effective as of January 1st, 2022 (the ?Effective Date?), is by and between Variation Biotechnologies Inc., a corporation incorporated pursuant to the laws of Canada (the ?Company?) having an address of 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1 and F. Diaz-Mitoma Professional Corporatio |
|
| February 25, 2022 |
Exhibit 99.1 VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union - Following positive CHMP recommendation, final EMA regulatory decision expected in coming months - European Union (EU) brand name to be PreHevbri? - If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine f |
|
| February 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| February 23, 2022 |
Exhibit 99.1 VBI Vaccines Announces PreHevbrio? [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults - PreHevbrio? is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - Vaccine availability is expected to begin later in Q1 2022 CAMBRIDGE, Mass. (February 23, 2022) ? VBI Vaccines Inc. (N |
|
| February 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| January 26, 2022 |
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference Exhibit 99.1 VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference CAMBRIDGE, M.A. ? January 26, 2022 ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D, VBI?s Chief Scientific Officer, will present an overview of VB |
|
| January 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 5, 2022 |
Exhibit 99.1 VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio - A second, two-part Phase 2a/2b study will assess the safety and efficacy of VBI-2601 (BRII-179) as an add-on therapy to standard-of-care treatment in chronic hepatitis B patients - Partner, Brii Biosciences, recently init |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2022 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| December 9, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada CAMBRIDGE, Mass. (December 9, 2021) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the filing of a New Drug Submission (NDS) to Health Can |
|
| December 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2021 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2021 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2021 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2021 |
Exhibit 99.1 VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021 ? Updated 12-month and 18-month overall survival data demonstrate continued improvements compared to historical controls1 ? 1 patient remaining on protocol has achieved progression-free survival beyond 86 weeks, demonstrating 93% tumor reduction rel |
|
| December 1, 2021 |
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults Exhibit 99.1 VBI Vaccines Announces FDA Approval of PreHevbrio? for the Prevention of Hepatitis B in Adults - PreHevbrio? is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - Shareholder conference call to be held today, December 1, at 8:30 AM ET CAMBRIDGE, Mass. (December 1, 2021) ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in |
|
| November 16, 2021 |
VBI Vaccines to Participate in Jefferies London Healthcare Conference Exhibit 99.1 VBI Vaccines to Participate in Jefferies London Healthcare Conference CAMBRIDGE, Mass. (November 16, 2021) ? VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the Jefferies London |
|
| November 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2021 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 8, 2021 |
Exhibit 10.5 Addendum of Unprotected Lease Agreement dated June 16, 2006 Drawn up and signed on the 24th day of the month of February 2016 Between: Ayalot Investments (Ramat Vered) 1994 Ltd Company No. 512022401 Of 7 Jabotinsky St., Ramat Gan (Hereinafter: ?the Lessor?) Of the first part; And between: SciVac Ltd Company No. 513679555 13 Gad Rd. Rehovot PO Box 580, 7610303 (Hereinafter: ?the Lessee |
|
| November 8, 2021 |
Exhibit 10.3 Addendum of Unprotected Lease Agreement dated right of use in floor protected space (?mamak?) Drawn up and signed on the 20th day of the month of October, 2006 Between: Africa Israel Properties Ltd Ayalot Investments (Ramat Vered) 1994 Ltd Sharda Ltd (Hereinafter: ?the Lessor?) Of the first part; And between: SciGen (IL) Ltd Company No. 513679555 42 HaYarkon St., Yavne 81227 (Hereinaf |
|
| November 8, 2021 |
Exhibit 10.8 Business Confidential ? Protected B THIS IS AN AMENDING AGREEMENT BETWEEN: NATIONAL RESEARCH COUNCIL OF CANADA a departmental corporation forming part of the Government of Canada created by the National Research Council Act (R.S.C. 1985, c. N-15), and an agent of Her Majesty the Queen in Right of Canada whose head office address is: 1200 Montreal Road Ottawa, Ontario K1A 0R6 (called t |
|
| November 8, 2021 |
Exhibit 10.2 Unprotected Lease Agreement Drawn up and signed on the 16th day of the month of June, 2006 Between: Africa Israel Properties Ltd Ayalot Investments (Ramat Vered) 1994 Ltd Sharda Ltd (Hereinafter: ?the Lessor?) Of the first part; And between: SciGen (IL) Ltd Company No. 513679555 42 HaYarkon St., Yavne 81227 (Hereinafter: ?the Lessee?) Of the second part; Whereas: The Lessor is the sol |
|
| November 8, 2021 |
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatitis B (HBV) : ? Prophylactic : FDA and EMA regulatory review of VBI?s 3-antigen prophylactic HBV vaccine candidate ongoing ? U.S. PDUFA target action date November 30, 2021 ? On November 3, the CDC?s ACIP unanimously passed a universal HBV vaccination recommendation for all adults age 19- |
|
| November 8, 2021 |
Exhibit 10.6 Addendum of Unprotected Lease Agreement dated June 16, 2006 Drawn up and signed on the [handwritten: 5th] day of the month of September 2016 Between: Ayalot Investments (Ramat Vered) 1994 Ltd Company No. 512022401 Of 7 Jabotinsky St., Ramat Gan (Hereinafter: ?the Lessor?) Of the first part; And between: SciVac Ltd Company No. 513679555 13 Gad Rd. Rehovot PO Box 580, 7610303 (Hereinaft |
|
| November 8, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2021 VBI VACCINES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37769 N/A (State or other jurisdiction of incorporation) (Commis |
